Liraglutida: La liraglutida, tambin desarrollada por Novo Nordisk, fue uno de los primeros agonistas GLP-1 aprobados para diabetes tipo 2 y, ms tarde, para el tratamiento de la obesidad
three random samples for each experimental condition were used for microarray analysis and all the four samples for quantitative polymerase chain reaction (qPCR) validation
By technically positioning the product as a research chemical rather than a drug intended for human use, vendors sidestep the FDA oversight that governs pharmaceutical products
Shrestha B, Reed JM, Starks PT, Kaufman GE, Goldstone JV, Roelke ME, et al
When administered in a clinical setting with pharmaceutical-grade peptides under medical supervision, the risk profile is substantially lower